FIGURE 3.

High numbers of stromal CD163⁺ TAMs are associated with adverse outcome. A, CD163 immunoreactivity was recorded intratumorally as in Fig. 1B; data are presented as mean immunoreactivity normalized to tissue compartments in percent. Cutoff values were determined using median CD163 expression to classify low-risk and high-risk groups; Kaplan–Meier curves are shown for each risk tier; log-rank test results are reported. B, CD163 immunoreactivity was recorded in the stroma as in A; Kaplan–Meier curves are shown for each risk tier; log-rank test results are reported.